






































Cost-effectiveness of direct oral anticoagulants
versus vitamin K antagonist in atrial fibrillation
A study protocol using Real-World Data from Catalonia
(FantasTIC Study)
Zojaina Hernández Rojas, MDa,b,c,d, Maria Rosa Dalmau Llorca, MD PhDa,b,c,d,
∗
, Carina Aguilar Martín, MD,
PhDb,d,e, Alessandra Queiroga Gonçalves, PhDb,d,f, Marc Casajuana, MScg,h, José Fernández-Sáez, PhDb,d,i,j,
Dolores Rodríguez Cumplido, PhDd,k, Emma Forcadell Drago, MD PhDd,l, Noèlia Carrasco-Querol, PhDb,
Josep Maria Pepió Vilaubí, MD PhDd,l, Josep M. Alegret, MD PhDm,n
Abstract
Background: Anticoagulant therapy is used for stroke prevention and proved to be effective and safe in the long term. The study
aims to analyse the cost-effectiveness relationship of using of direct-acting oral anticoagulants vs vitamin K antagonists to prevent
ischaemic stroke in patients with nonvalvular atrial fibrillation, including all the active ingredients marketed in Spain, prescribed for
2 years in the Primary Care service of the Institut Català de la Salut.
Methods: Population-based cohort study, in which the cost of the 2 treatment groups will be evaluated. Direct costs (pharmacy,
primary care, emergency and hospitalization) and indirect costs (lost productivity) will be included from a social perspective.
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Effectiveness (assessed as the occurrence of a health event, the 1 of primary interest being stroke) will be determined, with a 2-year
time horizon and a 3% discount rate. The average cost of the 2 groups of drugs will be compared using a regression model to
determine the factors with the greatest influence on determining costs. We will carry out a univariate (‘one-way’) deterministic
sensitivity analysis.
Discussion:We hope to provide relevant information about direct and indirect costs of oral anticoagulants, which, together with
aspects of effectiveness and safety, could help shape the consensual decision-making of evaluating bodies.
Abbreviations: DOACs = direct-acting oral anticoagulants, ICS = Institut Català de la Salut, NVAF = nonvalvular atrial fibrillation,
PC = primary care, VKAs = vitamin K antagonists.
Keywords: atrial fibrillation, cost effectiveness, primary health care, anticoagulants, oral drug administration
1. Introduction
Atrial fibrillation (AF) is the most common arrhythmia in western
countries and is associated with high morbidity and mortality,
thereby constituting a major public health problem.[1,2] It is 1 of
the most frequent causes of ischaemic stroke.[3,4] Anticoagulant
therapy is used for stroke prevention, for which there are 2 main
groups of drugs —vitamin K antagonists (VKAs) and direct-
acting oral anticoagulants (DOACs)— which have both proved
effective and safe in the long term.[5]
VKAs have been widely used for a long time and their efficacy
in preventing strokes and systemic embolism in patients with
nonvalvular atrial fibrillation (NVAF) is well established.[6]
However, most of the studies have involved warfarin, and the
results have been generalized to all VKAs.[7] The price of these
drugs is low (compared with that of DOACs),[8] although they
generate direct and indirect costs. Furthermore, they have
limitations such as interindividual and intraindividual variability
of response, a slow onset of action, a narrow therapeutic margin,
a need for dose-adjustment through periodic controls of the
international normalized ratio, and interactions with some foods
and medications.[9–11]
In recent years, DOACs have emerged that have more
predictable anticoagulant effects and fewer interactions with
other drugs, and that allow a fixed dosage regimen, without the
need for monitoring.[12] Overall, DOACs present a favorable risk
prevention profile, with significantly lower levels of strokes,
intracranial haemorrhages and mortality compared with VKAs,
but they have a higher risk of gastrointestinal bleeding[7] and are
expensive.[8] It is also important to take into account the
adjustment of the dosage according to age, weight, and renal
function, in addition to monitoring compliance, because highly
variable therapeutic adherence rates have been noted.[7,13]
The European and American guidelines recommend the use of
any DOACs rather than VKAs because of their net clinical
benefit, except in selected cases.[14–16] However, the use of
DOACs in clinical practice is determined by the recommenda-
tions of the health authorities of each country. In Spain, VKAs are
recommended as the first choice, with DOACs being used when
specifically recommended,[17] although currently it has been
observed that more than 80% of physicians are starting
treatments with DOACs .[18]
Previous studies found that DOACs tend to be more cost-
effective than VKAs for the treatment of AF.[19–23] One of these
studies suggest that rivaroxaban is cost-effective compared to
VKA, although the type of AVK and the dose thereof are not
specified.[23] A comparative study of the cost-utility of the first 3
DOACs to be marketed in Spain (apixaban, dabigatran and
rivaroxaban),[24] found dabigatran to be the most cost-useful. [25]
However, the most recent study carried out in Spain does not
show significant differences between dabigatran and AVKs.[26] A
recent study of edoxaban in Spain concluded that it is a cost-
effective alternative for this indication.[27] However, we did not
find any cost-effectiveness studies that included all the anti-
coagulants currently available on the market, with a population
base (without economic models) and real world data (RWD).
The main objective of the study will be to analyse the cost-
effectiveness of using DOACs in comparison with VKAs to
prevent ischaemic stroke in patients with NVAF, including all the
active ingredients marketed in Spain prescribed for 2 years in the
Primary Care (PC) service of the Institut Català de la Salut (ICS).
As secondary objectives, we intend to:
(1) determine the appearance of a health event, according to the
type of anticoagulation used (VKA or DOAC), and the
factors related to this;
(2) evaluate the cost in patients who are poorly controlled by
VKAs and under-treated with DOACs; and
(3) analyse the factors associated with increased costs.
The present study protocol, named FantasTIC (Non-valvular
atrial fibrillation and treatment, health assessment, Information
and Communication Technologies) study has been designed to
address these aspects.
2. Methodology
2.1. Design and study period
This is a population-based cohort study designed to evaluate
and compare the cost-effectiveness of the 2 types of
anticoagulant treatment (VKA and DOAC) in patients with
NVAF, with a time horizon of 2 years (from 1 January 2017 until
31 December 2018). The flow diagram of the study is presented
in Figure 1.
2.2. Study population
Our study population will be that treated by the PC service of the
ICS. The Autonomous Community of Catalonia has a health
service whose main provider is the ICS, in which PC is organized
into teams made up of family doctors, nurses, paediatricians,
social workers, dentists and support staff. The ICS manages,
among others, 287 PC centres (PCCs) to which 5,564,292
citizens are assigned (approximately 80% of the Catalan
population).[28]
As established by the Sistema de Información para el
Desarrollo de la Investigación en Atención Primaria (SIDIAP;
Information System for the Development of Research in PC),
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during the year 2017, 126,702 cases of NVAF had been
registered in the ICS, 61,002 of which were receiving anticoagu-
lant treatment (41,430 VKA and 19,548 DOAC).
Inclusion criteria:
(1) Patient with a diagnosis of NVAF at least 1 year old.
(2) Patient undergoing treatment with VKA or DOAC.
Exclusion criteria:
(1) Patient with indications for anticoagulation other than
NVAF.
(2) Pregnancy.
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Figure 1. Flow diagram.
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Data collection will end on 31December 2018 or sooner if any
of the following occurs:
(1) Anticoagulation prescription suspended for more than 180
days.
(2) Patient moves to another Autonomous Community.
(3) Patient becomes pregnant.
(4) Withdrawal of the diagnosis of NVAF.
(5) Appearance of a diagnosis of valvular AF.
(6) Death of the patient.
2.3. Data source
At ICS, more than 9175 professionals working in PC use the same
computerized medical history program, called eCAP. eCAP data
will be obtained through SIDIAP, which is a unique database,
previously validated, and highly representative of the Catalan
population.[29,30]
In this way, SIDIAP provides, from each of the 5.8 million
citizens assigned to the various PCCs of the ICS, information
linked to a unique, anonymised identifier. The following
information will be obtained from all NVAF patients receiving
anticoagulants on January 1, 2017:
(1) data from the eCAP program: demographic data, PC visits,
health events, clinical variables, referrals, deaths, prescrip-
tions and sick leave;
(2) laboratory results: these will be extracted directly from the
laboratory database, rather than depending on manual
records, thereby guaranteeing data quality;
(3) medication dispensed by pharmacy offices: this information
will be obtained directly from those offices;
(4) other, external sources of information: (4.1.) Conjunt Minim
Bàsic de Dades (CMBD), which is a population registry that
collects ICD-9 pathology data linked to hospitalization at all
of the Hospitals in Catalonia,[31] (4.2.) Mortality: data
supplied by the Department of Health, including cause and
date of all deaths of residents of Catalonia.[28]
2.4. Variables
The variables considered in the study will be divided into 5
groups: cost, follow-up, effectiveness, pharmacy, and those
corresponding to personal history (summarised in Table 1).
All oral anticoagulants that are marketed in Spain will be
included in the study:
Table 1
Variables, sampling period, and source of information.
Variables Baseline 1 year 2 years Source of information Source of costs
Personal history
Sociodemographic characteristics • • • eCAP
Primary care centre of origin • eCAP
Comorbidities • • • eCAP
CHA2DS2-VASc score • • • eCAP
HAS–BLED score • • • eCAP
Date of NVFA diagnosis • eCAP
Charlson comorbidity index • • • eCAP
Pharmacy variables
Anticoagulant • • • Pharmacy
Follow-up variables
Biannual TTR • • • eCAP
Estimated GF • • • eCAP
DOAC dosage • • • eCAP
Cost variables
Primary care visits • • eCAP DOGC
Hospital admissions • • CMBD-AH DOGC
Institutionalisations • • eCAP DOGC
Visits to specialists • • eCAP DOGC
Temporary disability • • eCAP INE
Laboratory tests • • Laboratory DOGC
Complementary tests • • CMBD-AH DOGC
Pharmaceutical expenses • • Pharmacy RPI, DH
Effectiveness variables
Ischemic stroke • • eCAP/CMBD-AH
Other thromboembolic episodes • • eCAP/CMBD-AH
Intracranial haemorrhage • • eCAP/CMBD-AH
Digestive haemorrhage • • eCAP/CMBD-AH
Other haemorrhages • • eCAP/CMBD-AH
Mortality • • DH
CMBD-AH=Conjunt Minim Bàsic de Dades - dates, diagnoses and procedures (ICD-9 Codes) linked to admissions in any of the hospitals in Catalonia, DH=Department of Health, DOAC=direct-acting oral
anticoagulant, DOGC=Diari Oficial de la Generalitat de Catalunya [Official Journal of the Government of Catalonia], eCAP=Estación Clínica de Atención Primaria [Clinical History of Primary Care], GF=glomerular
filtration, INE= Instituto Nacional de Estadística [National Statistics Institute], NVFA=nonvalvular atrial fibrillation, RPI= retail price index, TTR= time in therapeutic range.
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(1) VKAs: Acenocoumarol and warfarin.
(2) DOACs: Apixaban, dabigatran, edoxaban and rivaroxaban.
2.5. Cost estimation
Cost estimates will take into account direct expenses (from
pharmacy, PC, emergencies and hospitalisation) and indirect
expenses (loss of productivity), from a social perspective, in
patients diagnosed with NVAF and treatment with oral
anticoagulants. Two groupswill be established: patients receiving
VKAs and those receiving DOACs. We will use a 3% discount
rate, which will be applied in the second year.
We will use the charges set out in the Diari Oficial de la
Generalitat de Catalunya (DOGC)[32] closest to the date of
analysis (2014) to estimate the costs. The euro will be used as the
reference currency (which will not require conversion). Prices will
be adjusted to those of 2018 to take into account inflation in the
health sector.[33] The costs of hospital admissions will be
obtained from the Grups Relacionats amb el Diagnòstic
(GRD) patient classification system, published in the
DOGC.[34,35] For drug prices, the retail price taken from
pharmacy billing data will be used. The final costs of the 2
study groups (patients treated with VKAs and those treated with
DOACs) will be calculated by quantifying the resources
consumed by each individual with respect to each variable and
then multiplying by the cost of each resource. This procedure will
yield the total cost of the resource per individual, as well as the
total cost for each study group.
2.6. Measurement of effectiveness
The primary health event in this project will be “ischaemic
stroke” and the indicator of cost-effectiveness will be “avoided
strokes”. To estimate avoided strokes we will determine the total
economic cost for the 2 pharmacological groups, as well as the
number of strokes registered during the 2 years of the study
period. Finally, we will compare the groups and thereby
determine the economic cost of avoiding a stroke.
Secondarily, we will determine the appearance of the following
health events during the 2 years of the study:
 Ischaemic events:
(1) Ischemic stroke.
(2) Other thromboembolic events (transient ischaemic attack








The cost of DOACs will be compared with that of VKAs,
following the methodological guidelines for this type of study
proposed by the International Society for Pharmacoeconomics
and Outcomes Research (ISPOR)[36] and the International
Network of Agencies for Health Technology Assessment
(INAHTA).[37]
After comparing the average cost of both groups of drugs and
estimating their confidence intervals, a regression model will be
developed to determine which factors may have the most
substantial influence on determining costs. A generalized linear
model (GLM) will be derived, which, given the asymmetry of the
cost variable, will be based on the gamma family of distributions,
with a log link function,[38] because these give a best fit to the data
when estimating the impact of the factors associated with the
composition of patient costs.
2.8. Sensitivity analysis
A univariate (1-way) deterministic sensitivity analysis will be
carried out, in the items which the greatest impact on the
composition of the cost, or in which there may be a uncertainty
with the real price.[39] This will allow us to test the robustness of
our results.
3. Ethics and dissemination
This study will be carried out in accordance with the norms and
principles of the Declaration of Helsinki. The protocol was
approved by the Clinical Research Ethics Committee of the
Fundació Institut Universitari per a la recerca a l’ Atenció
Primària de salut Jordi Gol i Gurina (IDIAPJGol) on May 30,
2018 with code P18/080, and has also been authorized by the
Primary Healthcare Directorate of the ICS. The SIDIAP database
provides anonymised data, identified with an internal code,
which makes it impossible, even for the research team, to identify
any subject. For the same reason, informed consent will not be
obtained. By these means, the confidentiality of the data of the
individuals included in the study will be guaranteed, in
accordance with the Organic Law on Protection of Personal
Data (03/2018 of December 5, and in accordance with the
provisions of the Regulation 2016/679 of the European
Parliament and of the Council of 27 April 2016 on data
protection, and all applicable national regulations. If any
modification is required, it will be presented to the IDIAPJGol
Clinical Research Ethics Committee for approval.
The results and conclusions of this study will be disseminated
in Spain, as well as in international scientific and professional
forums, with the results published in indexed scientific journals.
4. Discussion
The aim of the present study is to carry out an economic
evaluation of all the anticoagulants indicated for the prevention
of thromboembolic complications in patients with NVAF.
VKAs are the most used anticoagulants worldwide.[40]
However, the administration criteria differs in each country.
For example, while in Continental Europe, the VKA most widely
used is the acenocoumarol, in the United States and the rest of
Europe, it is the warfarin.[41] Several studies have been carried out
with warfarin. [15,16,19,20,25,42] Though, there is scarce literature
on acenocoumarol, [21,22,24,27] which is the most popular VKA in
Spain. In the clinical practice, the results of the studies including
warfarin are assumed to be generalizable.[7] Nevertheless, and
from the best of our knowledge, there is no evidence to support
this assumption.
The main strength of our study is the analysis of all marketed
anticoagulants from Spain, which will provide strong evidence
about their differences, including both VKAs (warfarin and
acenocoumarol). Another strength includes the quantification of
indirect costs, such as the loss of productivity, associated with the
Hernández Rojas et al. Medicine (2020) 99:36 www.md-journal.com
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2 types of treatments. Since it is a population-based study, with
RWD, more accurate and representative information will be
available for health decision-makers.[43,44]Moreover, most of the
published research on this topic is based on hospital data,
whereas our project will include variables and expenses related to
PC settings, where most VKA controls are performed in our
milieu.
4.1. Limitations
Our study has certain limitations. First, the database includes data
that are dependent on the professional registry, which means that
theremay be some under-registration of some variables of interest.
In addition, there are expenses that we cannot determine, such as
those of medical transport or the journeys undertaken by patients
themselves, which could therefore lead to the costs of VKA being
underestimated. Also, we will not be able to include intangible
costs (as patient suffering due to complications or caregiver
overload) and operating costs, (such as overheads: water,
furniture, building maintenance and input costs). However, these
limitations should affect both groups of anticoagulants equally, so
it is reasonable to assume that they will not have a significant
impact on the result. Finally, a time horizon of 2 years could be too
short a time for a health event to occur.
4.2. Future directions
The evaluation of drugs with real-world data, based on cost-
effectiveness analyses, provides a valuable insight for other
European countries, where the conditions of use of these drugs
are usually similar.
This study could be of interest throughout Spain, as well as to
other countries with similar guidelines for treating NVAF, as it
will provide relevant information about direct and indirect costs,
which, together with aspects of effectiveness and safety, could
help shape the consensual decision-making of evaluating bodies,
and thereby provide a stimulus to update current consensus
documents. On the other hand, we consider that it would be
interesting for future research to include the opinions of patients
about their preferences for 1 type anticoagulant over another,
since this is a factor that could influence adherence to treatment
and, indirectly, its effectiveness and economic cost.
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